ArticleThe Journal of urology2026

Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum.

Neal D Shore et al.PubMed ↗Publisher ↗

No numbers read from the abstract.